Neurological Disorders

Mislabeled Muscle Spasm, Parkinson's Drugs Prompt Recall

By July 28, 2017

Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.

Ocrevus Effective in Reducing Multiple MS Progression Markers

By June 23, 2017

The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.

FDA Approves Brineura for Rare, Fatal Neurodegenerative Disease

By April 27, 2017

Results from the analysis showed the odds of Brineura-treated patients not having a decline were 13 times the odds of natural history cohort patients not having a decline (odds ratio 13.1, 95% CI: 1.2, 146.9).

Altered T-Cell Infusions Show Promise in Patients With Progressive MS

April 21, 2017

Over 6 months, the researchers said, none of the patients suffered serious side effects from the treatment. In addition, 3 showed symptom improvements within 2 to 8 weeks of their first T-cell infusion.

Tolerability, Adherence to Alzheimer's Drugs Assessed

By April 11, 2017

Overall, the researchers found no variation in tolerability or adherence to the 3 medications based on gender, race, education or age.

Gene Mutation for Early-Onset Parkinson's Disease ID'd

November 30, 2016

Mutated GCH1 gene tied to 23 percent increased risk of Parkinson's; symptoms five years earlier

FDA to Review Treatment for Levodopa-Induced Dyskinesia

By October 27, 2016

Adamas announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, to potentially treat levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

FDA-Approved Carnexiv Provides New Option for Certain Epilepsy Patients

By October 11, 2016

Carnexiv, an antiepileptic drug, is a short-term (≤7 days) intravenous (IV) replacement therapy for oral carbamazepine formulations in adults.

More Evidence that Zika Virus Can Cause Guillain-Barré Syndrome

October 06, 2016

Virus detected in body fluids of Colombians with Guillain-Barr syndrome

Potential ALS Treatment Under FDA Review

By August 30, 2016

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for edaravone (MCI-186; Mitsubishi Tanabe) for the treatment of amyotrophic lateral sclerosis (ALS).

Levetiracetam and Phenytoin Compared for Seizure Prophylaxis Following TBI

By July 12, 2016

A new meta-analysis found no evidence to suggest levetiracetam treatment is superior to phenytoin for early or late seizure prophylaxis in patients experiencing seizures following traumatic brain injuries (TBI)

Polygenic Scores May ID Those at Risk of Alzheimer's Disease

July 08, 2016

A genetic test may one day be able to predict the risk for Alzheimer's disease (AD) in young adults, according to a study published online July 6 in Neurology.

Study Examines QoL/Mood Outcomes of Adjunct Seizure Therapy, Lacosamide

By June 24, 2016

A 28-week open-label study of the adjunct antiepileptic drug, lacosamide, showed that it had a low risk of adverse mood effects and a low risk for overall effect on cognition.

Sabril REMS Update Ends OAF Requirement

By June 23, 2016

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Sabril (vigabatrin; Lundbeck) tablets, meaning prescribers will no longer be required to submit an ophthalmologic assessment form (OAFs) as part of the risk evaluation and mitigation strategy (REMS).

Tablet Splitting Can Significantly Vary Doses, FDA Study Finds

By June 23, 2016

An FDA report found that certain split tablets did not meet USPs Uniformity of Dosage Units accepted criteria.

NDA for Potential ALS Treatment Submitted to FDA

By June 21, 2016

Mitsubishi Tanabe Pharma announced that a New Drug Application has been submitted to the Food and Drug Administration (FDA) for edaravone (MCI-186) for the treatment of amyotrophic lateral sclerosis (ALS).

Company Halts Clinical Program for Ganaxolone in Adult Seizures

By June 15, 2016

Marinus Pharmaceuticals announced top-line results from the Phase 3 clinical trial of ganaxolone in adults with drug-resistant focal onset seizures.

Fycompa Oral Suspension Launched for Patients with Swallowing Difficulty

By June 15, 2016

Eisai announced the availability of Fycompa (perampanel) Oral Suspension for use in patients who have difficulty swallowing tablets or prefer liquids.

ANI Announces Approval, Launch of Two Generics

By June 14, 2016

ANI announced that the Food and Drug Administration (FDA) has approved Oxcarbazepine Tablets, the generic version of Novartis' Trileptal. In addition, ANI announced the launch of Oxycodone HCl Capsules.

Majority of Newly-Infected HIV Patients Display Neurological Symptoms

June 14, 2016

Many newly infected HIV patients experience neurological symptoms, but they tend to be mild and subside after initiation of antiretroviral treatment.

Complete Response Letter Issued to First Deuterated Drug Under FDA Review

By June 13, 2016

Teva announced that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) of SD-809 (deutetrabenazine) tablets for the treatment of chorea associated with Huntington's disease (HD).

Antiepileptic Granted Tentative Approval for Migraine Prophylaxis

By June 10, 2016

Upsher-Smith announced that the FDA has granted tentative approval for a supplemental New Drug Application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use in adults as prophylaxis of migraine headache.

Investigational Tx May Stop MS Symptoms Long-Term, but It's Risky

By June 09, 2016

An investigational multiple sclerosis (MS) treatment demonstrated the ability to stop relapses and new brain lesion development for a prolonged period without the need for ongoing medication, in a new phase 2 clinical trial.

Nuedexta Efficacy for PBA Evaluated Across Multiple Neurologic Disorders

By June 09, 2016

Avanir announced the publication of data from the PRISM II study that showed significant improvement of pseudobulbar affect (PBA) with Nuedexta (dextromethorphan HBr/quinidine sulfate) capsules in patients with Alzheimer's disease (AD) and other dementias, stroke, and traumatic brain injury (TBI).

New Drug-Free Option for RLS Launched

By June 09, 2016

Medi USA announced the launch of restiffic compressive foot wrap, a new drug-free option for patients with restless legs syndrome (RLS).

Risk of Birth Defects with Antiepileptic Drug Combos Examined

By June 08, 2016

New research suggests that the antiepileptic drug (AED) topiramate, when used in combination with other AEDs (excluding valproate) may enhance its propensity to cause fetal malformation.

Same Day Vaccine Combo May Up Risk of Febrile Seizures

June 07, 2016

Concomitant administration of inactivated influenza vaccine (IIV3) and pneumococcal conjugate vaccine (PCV) or diphtheria-tetanus-acellular-pertussis (DTaP)-containing vaccine is associated with an increased risk of febrile seizures (FS), according to a study published in Pediatrics.

Can Drinking Beer Help Protect Against Alzheimer's Disease?

By June 01, 2016

A new study of autopsies found that beer drinkers had a lower prevalence of Aß aggregation in the brain, one of the neuropathological lesions of Alzheimer's disease, compared to those who did not drink beer.

Can NSAID Use Lower the Risk of Cognitive Decline?

By June 01, 2016

The use of non-steroidal anti-inflammatory drugs (NSAIDs) may be linked to a reduced risk of cognitive decline, according to a meta-analysis published in Drugs & Aging.

Nuplazid Launched for Parkinson's Disease Psychosis

By May 31, 2016

Acadia announced the launch of Nuplazid (pimavanserin) tablets for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.